Identifying a "Range of Reasonable Options" for cervical cancer screening

Obstetrics and Gynecology

Volumn 125, Issue 2, 2015, Pages 308-310

  Sawaya, George F ^a   Kuppermann, Miriam ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER MORTALITY; CANCER RISK; CANCER SCREENING; COLPOSCOPY; COST BENEFIT ANALYSIS; CYTOLOGY; DISTRESS SYNDROME; HEALTH CARE COST; HUMAN; PAPILLOMAVIRUS INFECTION; PATIENT PREFERENCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; UTERINE CERVIX CANCER; FEMALE; MASS SCREENING; TIME FACTOR; UTERINE CERVIX TUMOR;

FEMALE; HUMANS; MASS SCREENING; PATIENT PREFERENCE; TIME FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 84922434167     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000000670     Document Type: Review

References (10)

1. Kinney W, Wright TC, Dinkelspiel HE, DeFrancesco M, Cox JT, Huh W. Increased cervical cancer risk associated with screening at longer intervals. Obstet Gynecol 2015; 125: 311-15
2. Silver MI, Rositch AF, Burke AE, Chang K, Viscidi R, Gravitt PE. Patient concerns about human papillomavirus testing and 5-year intervals in routine cervical cancer screening. Obstet Gynecol 2015; 125: 317-29
3. Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FAR, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Obstet Gynecol 2015; 125: 330-37
4. Kuppermann M, Pena S, Bishop JT, Nakagawa S, Gregorich SE, Sit A, et al. Effect of enhanced information, values clarification, and removal of financial barriers on use of prenatal genetic testing: a randomized clinical trial. JAMA 2014; 312: 1210-7
5. Moyer VA. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 156: 880-91, W312
6. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012; 62: 147-72
7. Screening for cervical cancer. Practice Bulletin Number 131. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012; 120: 1222-38
8. Wright TC Jr, Stoler MH, Behrens CM, Apple R, Derion T, Wright TL. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol 2012; 206: 46.e1-11
9. Sharp L, Cotton S, Cruickshank M, Gray NM, Harrild K, Smart L, et al. The unintended consequences of cervical screening: distress in women undergoing cytologic surveillance. J Low Genit Tract Dis 2014; 18: 142-50
10. Anderson JL, Heidenreich PA, Barnett PG, Creager MA, Fonarow GC, Gibbons RJ, et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2304-22